Lactate Biomarker May Predict Outcomes in Cardiogenic Shock
A review of cardiogenic shock studies suggests serial lactate measurements provide more prognostic information than isolated values and may better reflect treatment response.
By
Andrea Surnit
June 23, 2026
Clinical Scorecard: Lactate Biomarker May Predict Outcomes in Cardiogenic Shock
At a Glance
Category Detail
Condition Cardiogenic Shock Key Mechanisms Reduced cardiac output, systemic hypoperfusion, adrenergic stimulation, ischemia-reperfusion injury, systemic inflammation, mitochondrial dysfunction, impaired hepatic or renal clearance. Target Population Patients with cardiogenic shock Care Setting Intensive care and emergency settings
Key Highlights
Admission lactate levels are associated with shock severity and mortality. Lactate thresholds of 3 to 3.5 mmol/L indicate higher short-term mortality risk. Serial lactate monitoring reflects metabolic recovery and response to therapy. Early lactate clearance is a strong predictor of survival post-VA-ECMO initiation. Lactate should be interpreted as a dynamic biomarker reflecting metabolic stress and clearance. Guideline-Based Recommendations
Diagnosis
Use admission lactate levels to assess shock severity. Management
Monitor lactate levels serially to guide treatment and assess recovery. Monitoring & Follow-up
Track lactate clearance within the first 24 hours for survival prediction. Risks
Persistent hyperlactatemia despite adequate device flow is associated with poor outcomes. Patient & Prescribing Data
Patients undergoing treatment for cardiogenic shock, including those receiving VA-ECMO.
Epinephrine may elevate lactate levels, complicating clinical interpretation.
Clinical Best Practices
Integrate lactate values with clinical context for accurate assessment. Consider trajectory-based lactate assessment for risk stratification. Related Resources & Content
